Bolt Biotherapeutics
BOLT
24 hedge funds and large institutions have $2.49M invested in Bolt Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
14% more funds holding
Funds holding: 21 → 24 (+3)
0.52% more ownership
Funds ownership: 31.39% → 31.91% (+0.52%)
24% less capital invested
Capital invested by funds: $3.3M → $2.49M (-$807K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$160K |
| 2 |
Renaissance Technologies
New York
|
+$116K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$60.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$52.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$271K |
| 2 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$152K |
| 3 |
SC
Shay Capital
New York
|
-$1.91K |
| 4 |
Citigroup
New York
|
-$1.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$169 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Bank of America
Charlotte,
North Carolina
| – | -$169 | -31 | Closed |
|
BOLT Hedge Fund Activity: Q1 2026 in Review
24 of the 8,129 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q1 2026, worth a combined $2.49M — down 24% from $3.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BOLT positions and 2 closed out — a net gain of 4 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $160K. The largest seller was Pivotal bioVenture Partners Investment Advisor, cutting an estimated $271K.
- 24 institutional investors held Bolt Biotherapeutics (BOLT) as of Q1 2026, up from 21 in Q4 2025.
- Funds reported $2.49M of Bolt Biotherapeutics stock for Q1 2026, down 24% quarter-over-quarter.
- 6 funds opened new Bolt Biotherapeutics positions in Q1 2026 and 2 closed out, a net change of +4 holders.
- The largest Bolt Biotherapeutics buyer in Q1 2026 was Lynx1 Capital Management, an estimated $160K added.
- The largest Bolt Biotherapeutics seller in Q1 2026 was Pivotal bioVenture Partners Investment Advisor, an estimated $271K sold.
Based on aggregated 13F filings for Q1 2026.